Marksans Pharma Limited''s wholly owned subsidiary, Relonchem Limited receives Marketing Authorisation for its product Gabapentin 50 mg/ml oral solution from UK MHRA

pdf

Marksans Pharma Ltd.

09 May 2025

170.08

-0.72%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled a conference call for analysts and investors on Tuesday, May 20, 2025 at 05:00 PM (IST) to discuss the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2025.

pdf

Marksans Pharma Ltd.

08 May 2025

170.08

-0.72%

Board Meeting

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for To Consider And Approve Audited Financial …

BSE India

Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider and approve 1. To consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended March 31, 2025. 2. To consider recommendation of dividend on the equity shares for the financial year 2024-25, if any.

pdf

Marksans Pharma Ltd.

28 Apr 2025

170.08

-0.72%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

USFDA inspection at manufacturing facility of Company''s subsidiary Time-Cap Laboratories Inc.

pdf

Marksans Pharma Ltd.

10 Apr 2025

170.08

-0.72%

Company Update

Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Kindly find enclosed certificate from RTA under Reg. 74(5) of SEBI (DP) Regulations, 2018

pdf

Marksans Pharma Ltd.

31 Mar 2025

170.08

-0.72%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Cessation

BSE India

Pursuant to Reg 30 of SEBI (LODR) Reg 2015, Mr. SR Buddharaju - Independent Director has ceased to be an Independent Director of the Company upon completion of his tenure of two terms of 5 consecutive years w.e.f end of the day on March 31, 2025

pdf

Is Marksans Pharma Ltd. worth buying?

1422 Votes:

Buy 80.45%

Sell 10.2%

Hold 9.35%